Canada - English - Health Canada

mint pharmaceuticals inc - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas

Canada - English - Health Canada

mint pharmaceuticals inc - gliclazide - tablet (extended-release) - 60mg - gliclazide 60mg - sulfonylureas

Canada - English - Health Canada

jamp pharma corporation - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas

Canada - English - Health Canada

jamp pharma corporation - gliclazide - tablet (extended-release) - 60mg - gliclazide 60mg - sulfonylureas

Canada - English - Health Canada

sun pharma canada inc - gliclazide - tablet (extended-release) - 60mg - gliclazide 60mg - sulfonylureas

Canada - English - Health Canada

mylan pharmaceuticals ulc - gliclazide - tablet (extended-release) - 60mg - gliclazide 60mg - sulfonylureas

Canada - English - Health Canada

sun pharma canada inc - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas

United States - English - NLM (National Library of Medicine)

nostrum laboratories, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate tablets are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Canada - English - Health Canada

angita pharma inc. - gliclazide - tablet (extended-release) - 30mg - gliclazide 30mg - sulfonylureas

Canada - English - Health Canada

angita pharma inc. - gliclazide - tablet (extended-release) - 60mg - gliclazide 60mg - sulfonylureas